Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mustang Bio Inc MBIO

Healthcare Biotechnology
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene... see more

Recent & Breaking News (NDAQ:MBIO)

Mustang Bio to Present at the Virtual Fortress Biotech Corporate Access Summit

GlobeNewswire August 17, 2020

Mustang Bio Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency

GlobeNewswire August 17, 2020

Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020

GlobeNewswire August 12, 2020

Mustang Bio Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

GlobeNewswire August 10, 2020

Mustang Bio Announces Pricing of Public Offering of Common Stock

GlobeNewswire June 11, 2020

Mustang Bio Announces Proposed Public Offering of Common Stock

GlobeNewswire June 10, 2020

Mustang Bio to Host Virtual Annual Meeting of Stockholders

GlobeNewswire June 4, 2020

Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy

GlobeNewswire May 12, 2020

Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

GlobeNewswire May 11, 2020

Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency

GlobeNewswire April 20, 2020

Mustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire March 16, 2020

Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106

GlobeNewswire February 18, 2020

Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020

GlobeNewswire January 22, 2020

Mustang Bio to Participate in the Evercore ISI 2nd Annual HealthCONx Conference

GlobeNewswire December 2, 2019

Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire November 12, 2019

Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting

GlobeNewswire November 6, 2019

Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma

GlobeNewswire October 24, 2019

Mustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for Recently Opened First-of-Its-Kind Clinical Trial for Patients with Recurrent Malignant Glioma

GlobeNewswire October 10, 2019

Mustang Bio to Participate in October 2019 Investor Conferences

GlobeNewswire September 26, 2019

Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope

GlobeNewswire September 23, 2019